"Guideline development"

Guideline development

Short oral presentations

• Combining efforts/adapting guidelines
• A model for an international collaboration across organizations for developing clinical practice guidelines (S27)
  Holger J. Schunemann, MD, McMaster University, Hamilton, ON, Canada
• Adapting NICE guidance for a developing country: Pilot hypertension project with NICE International in Jordan (S15)
  Rachel O Mahony, PhD, NCGC, Royal College of Physicians, London, United Kingdom
• Adapting the ADAPTE Framework (S30)
  Ann Scott, PhD, Edmonton, AB, Canada
• Uniform user specifications to improve usability of external systematic reviews and guidelines (S16)
  Jeffrey S. Harris, MD, Kaiser Permanente Care Management Institute, Mill Valley, CA, USA
• eAGREE Training Tool: An electronic educational tool designed to improve a learner’s performance, satisfaction, and self-efficacy with the AGREE II (S113)
  Melissa C. Brouwers, PhD, McMaster University, Hamilton, ON, Canada
• Patient/family stakeholder roles
  
• Community members brought real life experience: An evaluation of lay people’s contribution to public health guidelines (S69)
  Jane Cowl, MSc, National Institute forHealth & Clinical Excellence, London, United Kingdom
• Involving decision makers in guidelines research: A case study (S71)
  Martin H. Reed, MD, Winnipeg, MB, Canada
• Patient involvement in Germany - How and when? (S73)
  Corinna Schaefer, German Agency for Quality in Medicine ÄZQ, Berlin, Germany
• Patient perspectives in clinical practice guideline (CPG): Participation and qualitative research (S74)
  Javier Gracia, Health Technology Assessment Unit, Madrid, Spain
• Patients initiate and lead the Multidisciplinary Guideline for Orofacial Pain (S75)
  Marianne van den Berg, PhD, Dutch Headache Patient Organisation, Bunde, Netherlands
• Consumer involvement in guideline development: early stage chronic kidney disease (S70)
  Allison Tong, PhD, University of Sydney, Sydney, NSW, Australia
• Stakeholder engagement in the scoping phase of clinical guideline development: Challenges and solutions (S76)
  Nichole Taske, PhD, NICE, London, United Kingdom
• Standardization of patient participation in guideline development (S77)
  Ilse Raats, PhD, Dutch Institute for Healthcare Improvement CBO, Utrecht, Netherlands
• Lessons for optimization of patient participation in guideline development: an action research approach (S72)
  Alida van der Ham, MSc, VU University Amsterdam, Amsterdam, Netherlands
• Turning evidence into recommendations
• A new approach to advice for guideline developers (S64)
  Nancy Huang, MPH, NHMRC’s National Institute of Clinical Studies, Hampton, VIC, Australia
• Experiences with the application of a tool to structure the process from conclusion to recommendation in a transparent way (S20)
  Sonja Kersten, Association of Comprehensive Cancer Centres, Utrecht, Netherlands
• Guiding urology practice: the american urological association’s (AUA) new guideline development process (S38)
  Heddy Hubbard, PhD, American Urological Association, Linthicum, MD, USA
• How mixed treatment comparisons can aid decision making in guidelines with limited or poor quality evidence (S39)
  Katrina L. Sparrow, MSc, National Clinical Guidelines Centre, London, United Kingdom
• Using and adapting GRADE methodology in an area of low quality evidence: An example from a national guideline on ablative therapies for the treatment of Barrett’s oesophagus (S22)
  Jonathan Nyong, MPH, National Institute for Health and Clinical Excelle, Manchester, United Kingdom
• Critical topics in guideline development
• A framework to improve guidelines for patients with multimorbidity (S59)
  Cynthia Boyd, MD, Johns Hopkins, Towson, MD, USA
• Rapid development and implementation of guidelines for infant neuroprotection with antenatal magnesium sulphate (MgS04) (S44)
  Philippa F. Middleton, The University of Adelaide, North Adelaide, S A, Australia
• The network guideline: A new model of developing a multidisciplinary guideline (S47)
  Tjerk Wiersma, MD, Dutch College of General Practioners, Utrecht, Netherlands
• “Less is more”: The minimal dataset in reviews for guidelines (S48)
  Maggie Westby, PhD, National Clinical Guideline Centre, London, United Kingdom
• The network approach: A feasible method in clinical guideline development (S49)
  Elvira M.E. Den Breejen, MD, Radboud University Medical Center Nijmegen, Nijmegen, Netherlands
• Guidelines and patient safety
• Developing a systematic approach to link CPG and patient safety (S50)
  Ignacio Marin-Leon, PhD, Valme University Hospital. Fundacion Enebro, Seville, Spain
• Developing patient safety evidence-based care Recommendations to improve child outcomes (S51)
  Karen J. Vonderhaar, MS, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA
• Using GRADE
• Attitudes of guideline development groups to use of GRADE in evidence evaluation and development of recommendations (S29)
  Victoria J. Kelly, National Institute Health and Clinical Excellence, Manchester, United Kingdom
• Experiences Presenting GRADE to the Guideline Development Group on the NICE Lower Urinary Tract Symptoms (LUTS) Guideline (S36)
  Clare N. Jones, MSc, National Clinical Guideline Centre, London, England, United Kingdom
• GRADE Imprecision Criteria: Interpretation and Impact on the NICE Lower Urinary Tract Symptoms in Men Guideline (S37)
  Lee- Yee Chong, PhD, National Clinical Guidelines Centre (NCGC), London, United Kingdom
• Implementing GRADE in an established national guideline program (S21)
  Robin T. Harbour, BSc, Scottish Intercollegiate Guidelines network, Glasgow, Scotland, United Kingdom
• Using the GRADE approach to develop diagnostic guidelines in allergic disease: The World Allergy Organization’s Diagnosis and Rationale for Action against Cow Milk Allergy (DRACMA) Guidelines (S14)
  Airton Tetelbom Stein, MD, Public
• Disease-oriented guideline development
• Balance@Work: A combined guideline and research project on prevention of weight gain among employees (S31)
  Carel Hulshof, PhD, Centre of Excellence, NVAB, Utrecht, Netherlands
• Development and institutionalization of disease management guidelines in Germany (S33)
  Thomas Langer, German Agency for Quality in Medicine ÄZQ, Berlin, Germany
• KP Integrated cardiovascular disease (cvd) risk reduction guidelines (S42)
  Craig Robbins, MD, Care Management Institute, Kaiser Permanente, Dever, OR, USA
• The development of recommendations for optimal organization of care in Parkinson’s disease (S46)
  Samyra HJ Keus, PhD, Radboud University Nijmegen Medical Center, Nijmegen, Netherland
• Guideline quality appraisal
• Compatibility of AGREE and clinical experts review in guideline appraisal (S24)
  Ken N. Kuo, MD, National Health Research Institutes, Taiwan, Miaoli County, Taiwan ROC
• How to develop new methods for systematic evaluation of internal validity of CPG recommendations (S26)
  Michaela Eikermann, MD, IQWiG, Cologne, Germany
• Just finished developing a guideline: how did we do? A process evaluation (S41)
  Christa Harstall, MHSA, Institute of Health Economics, Edmonton, AB, Canada
• Guidelines for patients
• Cancer survivorship plan in the Netherlands: A guideline for professionals in the oncology (S65)
  Sonja Kersten, MSc, Association of Comprehensive Cancer Centres, Utrecht, Netherlands
• Developing patients´ versions: the experience from a clinical practice guideline (CPG) for autistic spectrum disorders (ASD) (S56)
  Javier Gracia, Health Technology Assessment Unit, Madrid, Spain
• Low back interventions and opioid treatment guidelines: Comparison between ACOEM and APS (S43)
  Christopher J. Wolfkiel, ACOEM, Elk Grove Village, IL, USA
• Patient guidelines in oncology: A comparison of international standards and methodologies (S57)
  Markus Follmann, MD, German Cancer Society, Berlin, Germany
• The role of patients, family and stakeholders in guideline development: Meta-ethnography of qualitative research on peer support in chronic disease (S58)
  Mary J. Bell, MD, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
• Guidelines in developing countries
• Clinical practice guidelines production and its correlation with developmental status of countries: Analysis in Iberoamerican
  countries (S60)
  Iñaki Gutiérrez-Ibarluzea, PhD, Osteba Basque Office for HTA, Vitoria-Gasteiz, Spain
• Elaboration of a topic prioritization instrument for the development of clinical practice guidelines (CPGs) in Colombia (S35)
  Ricardo Sanchez, MD, Instituto Nacional de Cancerologia - UNAL, Bogotá, Colombia
• From evidence to practice in countries where health policy is not evidence-based (S7)
  Hayfaa A. Wahabi, MBBS, Al Riyadh, Saudi Arabia
• Transnational collaboration in developing ADAPTE clinical guidelines and use of GRADE when making recommendations: Experiences from Costa Rica, Panama and Guatemala. (S61)
  Mario G. Tristan, MD, IHCAI Foundation- Central America Cochrane Branch-, San Jose, Costa Rica
• Updating and archiving guidelines
• Analysis of chronic respiratory disease guideline updates of the past 10 years (S78)
  Liat Fishman, MD, German Agency for Quality in Medicine ÄZQ, Berlin, Germany
• Development of revised recommendations for hiv counseling, testing, and linkage in non-health-care settings (S34)
  Rebecca L. Morgan, MPH, Centers for Disease Control and Prevention, Atlanta, GA, USA
• Inventory of cancer guidelines: An approach for guideline dissemination, quality appraisal and information sharing (S80)
  Melissa C. Brouwers, PhD, McMaster University, Hamilton, ON, Canada
• Occupational medicine guidelines mandated by states: Experience with state rule making and regulatory agencies (S81)
  Christopher J. Wolfkiel, ACOEM, Elk Grove Village, IL, USA
• Ethical issues and conflict of interest
• Conflicts of interest: What to do when things go wrong: A case study. (S17)
  Rosina M. Ullman, PhD, NCC Women’s and Children’s Health, Sutton, England, United Kingdom
• Ethical aspects in CPGs: Explicit or implicit (S25)
  Radim Licenik, MD, University Hospital of North Staffordshire, Stoke on Trent, United Kingdom
• Ethics and guidelines, ethics in guidelines? Ethical chapters in CPGs on dilemmas in work and health (S68)
  Arnolda Petra Nauta, PhD, The Netherlands Society of Occupational Medicine, Delft, Netherlands
• Gender analysis of clinical practice guidelines for depression from four European countries: Austria, Finland, Sweden, and the United Kingdom (S19)
  Susanne Weinbrenner, MD, German Agency for Quality in Medicine ÄZQ, Berlin, Germany
• The vexing problem of guidelines and conflict of interest: A potential solution (S18)
  Holger J. Schunemann, MD, McMaster University, Hamilton, ON, Canada
• Guidelines for allied health professionals
• Challenges to developing guidelines for a public dental service (S53)
  Carmel Parnell, MPH, Oral Health Services Research Centre, Cork, Ireland
• Development of Pharmacist-specific Diabetes Guidelines (S54)
  Rosemary M. Killeen, BScPharm, Canadian Pharmacists Journal, Ottawa, ON, Canada
• Involving stakeholders in developing multidisciplinary and cross-sectoral clinical practice guidelines in social services (S55)
  Jean-Pierre Duplantie, DrPH, AETMIS, Montreal, QC, Canada

Workshops

• Medical societies and G-I-N: A win-win collaboration (W4)
• Richard Rosenfeld, MD, Amer Acad Otolaryngology - Head & Neck Surgery, Brooklyn, NY, USA
• David Nielsen, MD, Amer Acad Otolaryngology - Head & Neck Surgery, Alexandria, VA, USA
• Norman Kahn, MD, Council of Medical Specialty Societies, Chicago, IL, USA
• David D. Gutterman, MD, FCCP, Medical College of Wisconsin, Milwaukee, WI, USA
• Jako Burgers, PhD, Dutch Institute for Healthcare Improvement CBO, Nijmegen, Netherlands
• Critical appraisal instruments for (methodological) search filters for efficient information retrieval for guideline topics (W5)
• Rikie Deurenberg, MSc, Dutch Institute for Healthcare Improvement CBO, Utrecht, Netherlands
• Marjo Poth, MSc, Dutch Institute for Healthcare Improvement CBO, Utrecht, Netherlands
• Leena M. Lodenius, Finnish Medical Society Duodecim, Helsinki, Finland

• Cutting across national boundaries: Using the C-section to promote guidance development (W6)
• Craig J. Whittington, PhD, National Collaborating Centre for Mental Health, London, United Kingdom
• Seda Usubütün, MD, Ankara, Turkey
• Developing dynamic tobacco control guidelines in Canada (W7)
• Peter Selby, MBBS, Centre for Addiction and Mental Health -CAN-ADAPTT, Toronto, ON, Canada
• Applicability of clinical practice guidelines to patients with comorbid conditions: How to address comorbidity in guidelines (W8)
• Marjolein Lugtenberg, MSc, Tilburg University, TRANZO, Tilburg, Netherlands
• Klara Brunnhuber, PhD, BMJ Group, London, United Kingdom
• James Woodcock, MD, London School of Hygiene and Tropical Medicine, London, United Kingdom
• Gert Westert, PhD, Tilburg University, TRANZO, Tilburg, Netherlands
• Jako Burgers, PhD, IQ Healthcare, Nijmegen, Netherlands

• A quality-driven, pragmatic approach to crafting guideline action statements and evidence profiles (W9)
• Richard Rosenfeld, MD, American Academy of Otolaryngology - H&N Surg, Brooklyn, NY, USA
• Richard Shiffman, MD, Yale University, New Haven, CT, USA